- Home
- ILAG vs MIRA Comparison
ILAG vs MIRA Comparison
Compare ILAG & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- MIRA
- Stock Information
- Founded
- ILAG 1981
- MIRA 2020
- Country
- ILAG Hong Kong
- MIRA United States
- Employees
- ILAG N/A
- MIRA N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- ILAG Consumer Discretionary
- MIRA Health Care
- Exchange
- ILAG Nasdaq
- MIRA Nasdaq
- Market Cap
- ILAG 18.4M
- MIRA 17.1M
- IPO Year
- ILAG 2022
- MIRA 2023
- Fundamental
- Price
- ILAG $0.98
- MIRA $1.05
- Analyst Decision
- ILAG
- MIRA Strong Buy
- Analyst Count
- ILAG 0
- MIRA 2
- Target Price
- ILAG N/A
- MIRA $14.00
- AVG Volume (30 Days)
- ILAG 47.1K
- MIRA 552.1K
- Earning Date
- ILAG 11-29-2024
- MIRA 11-11-2024
- Dividend Yield
- ILAG N/A
- MIRA N/A
- EPS Growth
- ILAG N/A
- MIRA N/A
- EPS
- ILAG N/A
- MIRA N/A
- Revenue
- ILAG $6,443,357.00
- MIRA N/A
- Revenue This Year
- ILAG N/A
- MIRA N/A
- Revenue Next Year
- ILAG N/A
- MIRA N/A
- P/E Ratio
- ILAG N/A
- MIRA N/A
- Revenue Growth
- ILAG N/A
- MIRA N/A
- 52 Week Low
- ILAG $0.33
- MIRA $0.51
- 52 Week High
- ILAG $1.35
- MIRA $6.40
- Technical
- Relative Strength Index (RSI)
- ILAG 44.56
- MIRA 38.97
- Support Level
- ILAG $0.97
- MIRA $1.04
- Resistance Level
- ILAG $1.06
- MIRA $1.20
- Average True Range (ATR)
- ILAG 0.06
- MIRA 0.07
- MACD
- ILAG -0.01
- MIRA 0.02
- Stochastic Oscillator
- ILAG 16.32
- MIRA 19.44
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc is engaged in the business of manufacturing and selling mechanical locksets. The business is spread across the Unites States, Canada, Australia, and China. Majority of the revenue is generated from the United States.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.